Search results
Showing 1381 to 1395 of 1455 results for ages
Adrenal insufficiency: identification and management (NG243)
This guideline covers identifying and managing adrenal insufficiency (hypoadrenalism) in babies, children, young people and adults. It aims to improve the treatment of primary, secondary and tertiary adrenal insufficiency, and the prevention and management of adrenal crisis.
This guideline covers when to offer and discuss caesarean birth, procedural aspects of the operation, and care after caesarean birth. It aims to improve the consistency and quality of care for women and pregnant people who are thinking about having a caesarean birth or have had a caesarean birth in the past and are now pregnant again.
Evidence-based recommendations on natalizumab originator (Tysabri) and biosimilar (Tyruko) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy in adults.
NICE has developed a medtech innovation briefing (MIB) on plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer .
Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma (TA524)
Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating CD30-positive Hodgkin lymphoma in adults.
This guideline covers support for adults (aged 18 and over) who provide unpaid care for anyone aged 16 or over with health or social care needs. It aims to improve the lives of carers by helping health and social care practitioners identify people who are caring for someone and give them the right information and support. It covers carers’ assessments, practical, emotional and social support and training, and support for carers providing end of life care.
This guideline covers integrated diagnostic reporting for diagnosing haematological cancer in adults, young people and children. It also covers staffing, facilities (levels of care) and multidisciplinary teams needed for adults and young people. It aims to improve care for people with suspected or diagnosed cancer by promoting best practice on the organisation of haematological cancer services.
View recommendations for NG47Show all sections
Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)
Evidence-based recommendations on ticagrelor (Brilique) for preventing atherothrombotic events after myocardial infarction in adults.
This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
How we collect and use your personal information, and your rights under data protection legislation.
Virtual chromoendoscopy to assess colorectal polyps during colonoscopy (HTG438)
Evidence-based recommendations on virtual chromoendoscopy (VCE) using NBI, FICE or i-scan to assess colorectal polyps of 5 mm or less during colonoscopy.
This quality standard covers assessing and diagnosing fetal alcohol spectrum disorder (FASD) in children and young people. It also covers support during pregnancy to prevent FASD. It describes high-quality care in priority areas for improvement.
View quality statements for QS204Show all sections
Spinal metastases and metastatic spinal cord compression (NG234)
This guideline covers recognition, referral, investigation and management of spinal metastases and metastatic spinal cord compression (MSCC). It is also relevant for direct malignant infiltration of the spine and associated cord compression. It aims to improve early diagnosis and treatment to prevent neurological injury and improve prognosis.
High-throughput non-invasive prenatal testing for fetal RHD genotype (HTG420)
Evidence-based recommendations on high-throughput non-invasive prenatal testing (NIPT) for fetal RHD genotype.
Esketamine nasal spray for treatment-resistant depression (TA854)
Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.